Online event: “Technologies to Tackle Substandard and Falsified Medical Products in Global Health” Dear Friends, With apologies for any double posting, I am forwarding on behalf of Kate Enright the information concerning this upcoming online event. Please note that it is organized in a way that may give also to non-academic actors (e.g., those working ...
Dear Friends, As we know, substandard and falsified (SF) medical products negatively affect patients’ safety and health outcomes, health systems’ financial sustainability, public trust in health systems, and they are a co-cause of antimalarials and antimicrobial resistance. Therefore, sound research on SF medical products is important in order to raise awareness, to understand the causes ...
210923 BCH/QUAMED: Quality of medical products for cardiovascular diseases Ref: Do NT, Bellingham K, Newton PN, et al. The quality of medical products for cardiovascular diseases: a gap in global cardiac care. BMJ Global Health 2021;6:e006523. doi:10.1136/bmjgh-2021-006523 Dear Friends, Today, I would like to share an important research paper from our IDDO friends in Oxford. The ...
Be-cause Health & QUAMED literature updates Ref: World Health Organization. Regulatory guidance for assessment and management of applications for marketing authorization of oxytocin. WHO 2021. ISBN 978-92-4-002213-3 (electronic version). Dear Friends, Today, I would like to share a WHO regulatory document concerning the quality of oxytocin-containing products. You can download it at this link: https://www.who.int/publications/i/item/9789240022133 ...
Be-cause Health & QUAMED literature updates Ref (1): US Pharmacopoeia, Increasing Transparency in the Medicines Supply Chain, 2021 Ref (2): US Pharmacopoeia, Global Public Policy Position: Key Elements to Building a More Resilient Supply Chain Dear Friend, The more diffuse and fragmented the supply chain is, the greater the risk that important information about the origin, production ...
Be-cause Health & QUAMED literature updates · Ref. Bourasseau, A., Lavergne, L. & Ravinetto, R. Assessments of the quality systems of pharmaceutical distributors: a remote approach to be applied in times of COVID-19 and beyond. J of Pharm Policy and Pract 2021; 14, 43 Dear Friend, Today, I would like to present a very recent publication, which just appeared in ...
Be-cause Health & QUAMED literature updates Ref. Tuck C et al. Quality assurance and cancer medicines in low-income and middle-income countries. Lancet Oncol 2021; 22: 301-3. Available at https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00055-3/fulltext?rss=yes Dear Friend, I would like to highlight a short but important commentary from Tuck and colleagues, raising awareness on the quality challenges for cancer medicines available in ...
Be-cause Health & QUAMED literature updates Ref Hauk C, SchafermannS, Martus P, Muzafarova N, Babaley M, Waning B, et al. (2020) Quality assurance in anti-tuberculosis drug procurement by the Stop TB Partnership—Global Drug Facility: Procedures, costs, time requirements, and comparison of assay and dissolution results by manufacturers and by external analysis. PLoS ONE 15(12): e0243428. ...
Be-cause Health & QUAMED literature updates Ref. Ndomondo-SigondaM, Mahlangu G, Agama-Anyetei M, Cooke E (2020) A new approach to an old problem: Overview of the East African Community’s MedicinesRegulatory Harmonization initiative. PLoS Med 17(8):e1003099. https://doi. org/10.1371/journal.pmed.1003099 Dear Friend, The capacity to regulate medical products is key for ensuring the quality, safety, and efficacy of medical ...
Would you like more information about audits or get a quote? Do not hesitate to contact us via the contact form.
En poursuivant votre visite sur ce site, vous acceptez l'utilisation de cookies En savoir plus
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.